Fibriant expands license adding recombinant human (pro)thrombin to existing recombinant fibrinogen capability – Company on track for clinical studies with RecoSeelTM in mild-to-moderate bleeding in 2021
Leiden, The Netherlands, December 5, 2019 - Fibriant B.V., a developer of innovative recombinant fibrin(ogen) technology and products, today announced [...]